

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-190) ZEDENOLEUCEL
PRONUNCIATION ze den" oh loo' sel
THERAPEUTIC CLAIM Treatment of acute myeloid leukemia (AML)

DESCRIPTION

Cell source: HSCT donor Cellular identity: T cells

Culture conditions (manufacturing protocol): The drug product is multi-tumor-associated antigen (TAA) specific T lymphocytes. The manufacturing process selectively amplifies tumor-targeted T cell precursors ex vivo using antigen presenting cells (APCs) expressing a range of TAAs that are selectively overexpressed on leukemic cells. The stimulation is performed using aseptic methods and clinical grade peptide mixtures. Donor T cells are cultured with autologous APCs loaded with the peptide mixtures spanning the entire primary sequences of the four tumor associated antigens PRAME, NY-ESO-1, Survivin, and WT1 in the presence of recombinant cytokines to stimulate T cell growth.

TRADEMARK None as yet
SPONSOR Marker Therapeutics, Inc.
CODE DESIGNATIONS MT-401
UNII L4D9X59F34
WHO NUMBER 11796

SCS